- Home
- CLLS vs DRTS Comparison
CLLS vs DRTS Comparison
Compare CLLS & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- DRTS
- Stock Information
- Founded
- CLLS 1999
- DRTS 2015
- Country
- CLLS France
- DRTS Israel
- Employees
- CLLS N/A
- DRTS N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- CLLS Health Care
- DRTS Health Care
- Exchange
- CLLS Nasdaq
- DRTS Nasdaq
- Market Cap
- CLLS 299.0M
- DRTS 300.2M
- IPO Year
- CLLS 2007
- DRTS N/A
- Fundamental
- Price
- CLLS $3.49
- DRTS $4.20
- Analyst Decision
- CLLS Buy
- DRTS Strong Buy
- Analyst Count
- CLLS 1
- DRTS 1
- Target Price
- CLLS $8.00
- DRTS $9.00
- AVG Volume (30 Days)
- CLLS 212.5K
- DRTS 60.0K
- Earning Date
- CLLS 11-03-2025
- DRTS 11-18-2025
- Dividend Yield
- CLLS N/A
- DRTS N/A
- EPS Growth
- CLLS N/A
- DRTS N/A
- EPS
- CLLS N/A
- DRTS N/A
- Revenue
- CLLS $63,438,000.00
- DRTS N/A
- Revenue This Year
- CLLS N/A
- DRTS N/A
- Revenue Next Year
- CLLS $66.76
- DRTS N/A
- P/E Ratio
- CLLS N/A
- DRTS N/A
- Revenue Growth
- CLLS 223.09
- DRTS N/A
- 52 Week Low
- CLLS $1.10
- DRTS $2.14
- 52 Week High
- CLLS $5.48
- DRTS $4.69
- Technical
- Relative Strength Index (RSI)
- CLLS 47.81
- DRTS 56.64
- Support Level
- CLLS $3.39
- DRTS $3.97
- Resistance Level
- CLLS $5.48
- DRTS $4.34
- Average True Range (ATR)
- CLLS 0.38
- DRTS 0.28
- MACD
- CLLS -0.10
- DRTS -0.01
- Stochastic Oscillator
- CLLS 6.38
- DRTS 64.29
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.